XIFAXAN safety and dosing

XIFAXAN has a demonstrated safety profile1

Percentage of HE patients taking XIFAXAN, with adverse reactions occurring at an incidence of ≥10% and at a higher rate than placebo in a randomized, double-blind, multicenter clinical trial.1

For patients with OHE, XIFAXAN dosing is convenient1

Compliance is important to the treatment of any chronic condition. The dosing of XIFAXAN is convenient for patients with overt HE.1

  • One 550 mg tablet, twice daily–no dose adjustments or titrations needed1*
  • Can be taken with or without food1
  • Can be continued for as long as patient is at risk of recurrent OHE1†

*There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

The safety and efficacy of XIFAXAN in HE have not been studied beyond 6 months in randomized, placebo-controlled clinical trials.1

See how XIFAXAN cut the risk of overt HE recurrence and HE-related hospitalization in half1

HE = hepatic encephalopathy

The ICD-10 Codes and all other patient access related information are provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.